# ğŸ“š startup survival rates time profitability first year - è«–æ–‡æ¤œç´¢çµæœ

> ğŸ” **æ¤œç´¢ã‚¯ã‚¨ãƒª**: startup survival rates time profitability first year
> ğŸ“… **æ¤œç´¢æ—¥æ™‚**: 2025-08-02 17:15:20
> ğŸ¯ **å°‚é–€åˆ†é‡**: general_research
> ğŸ§  **æ€è€ƒãƒ¢ãƒ¼ãƒ‰**: general
> ğŸ“Š **å–å¾—è«–æ–‡æ•°**: 5ä»¶

## ğŸ“‹ æ¤œç´¢æ¦‚è¦

### ğŸ“ˆ æ¤œç´¢çµ±è¨ˆ
- **ç·æ¤œç´¢æ•°**: 5ä»¶
- **ãƒ•ã‚£ãƒ«ã‚¿å¾Œ**: N/Aä»¶
- **æœ€çµ‚çµæœ**: 5ä»¶

## ğŸ“„ è«–æ–‡ä¸€è¦§

### 1. ğŸ“„ Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Nonâ€“Small-Cell Lung Cancer in CheckMate 227

**åŸºæœ¬æƒ…å ±**:
- **è‘—è€…**: J. Brahmer, Jong-Seok Lee, T. Ciuleanu, R. BernabÃ© Caro, M. Nishio, L. Urban, C. Audigier-Valette, L. Lupinacci, R. Sangha, A. PÅ‚uÅ¼aÅ„ski, J. Burgers, M. Mahave, Samreen Ahmed, A. Schoenfeld, L. Paz-Ares, M. Reck, H. Borghaei, K. O'Byrne, Ravi G. Gupta, J. Bushong, Li Li, S. Blum, Laura J. Eccles, S. Ramalingam
- **ç™ºè¡¨å¹´**: 2022
- **å¼•ç”¨æ•°**: 173
- **ã‚¸ãƒ£ãƒ¼ãƒŠãƒ«**: Journal of Clinical Oncology

- **DOI**: https://doi.org/10.1200/JCO.22.01503
- **URL**: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.01503?role=tab

**æ¦‚è¦**: PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic nonâ€“small-cell lung cance...

**ç·åˆã‚¹ã‚³ã‚¢**: 31.0

---

### 2. ğŸ“„ Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donorâ€specific antibodies in the first year of kidney transplantation

**åŸºæœ¬æƒ…å ±**:
- **è‘—è€…**: S. Davis, J. Gralla, P. Klem, Suhong Tong, G. Wedermyer, B. Freed, A. Wiseman, J. Cooper
- **ç™ºè¡¨å¹´**: 2018
- **å¼•ç”¨æ•°**: 124
- **ã‚¸ãƒ£ãƒ¼ãƒŠãƒ«**: American Journal of Transplantation

- **DOI**: https://doi.org/10.1111/ajt.14504
- **URL**: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.14504

**æ¦‚è¦**: De novo donorâ€specific antibodies (dnDSAs) have been associated with reduced graft survival. Tacrolimus (TAC)â€“based regimens are the most common among immunosuppressive approaches used in in clinical ...

**ç·åˆã‚¹ã‚³ã‚¢**: 30.7

---

### 3. ğŸ“„ Analysing lapsing rates among first-time blood donors at a blood centre in Zimbabwe using survival analysis

**åŸºæœ¬æƒ…å ±**:
- **è‘—è€…**: Coster Chideme, Delson Chikobvu
- **ç™ºè¡¨å¹´**: 2024
- **å¼•ç”¨æ•°**: 0
- **ã‚¸ãƒ£ãƒ¼ãƒŠãƒ«**: The Pan African Medical Journal

- **DOI**: https://doi.org/10.11604/pamj.2024.47.211.39015
- **URL**: https://doi.org/10.11604/pamj.2024.47.211.39015

**ç·åˆã‚¹ã‚³ã‚¢**: 21.5

---

### 4. ğŸ“„ Digital transformation: A multidisciplinary reflection and research agenda

**åŸºæœ¬æƒ…å ±**:
- **è‘—è€…**: Peter C. Verhoef, Thijs Broekhuizen, Yakov Bart, Abhi Bhattacharya, John Qi Dong, Nicolai Etienne Fabian, Michael Haenlein
- **ç™ºè¡¨å¹´**: 2019
- **å¼•ç”¨æ•°**: 3345
- **ã‚¸ãƒ£ãƒ¼ãƒŠãƒ«**: Journal of Business Research

- **DOI**: https://doi.org/10.1016/j.jbusres.2019.09.022
- **URL**: https://doi.org/10.1016/j.jbusres.2019.09.022

**æ¦‚è¦**: Digital transformation and resultant business model innovation have fundamentally altered consumers' expectations and behaviors, putting immense pressure on traditional firms, and disrupting numerous ...

**ç·åˆã‚¹ã‚³ã‚¢**: 17.7

---

### 5. ğŸ“„ The first year of doctoring: still a survival exercise

**åŸºæœ¬æƒ…å ±**:
- **è‘—è€…**: John Bligh
- **ç™ºè¡¨å¹´**: 2002
- **å¼•ç”¨æ•°**: 0
- **ã‚¸ãƒ£ãƒ¼ãƒŠãƒ«**: Medical Education

- **DOI**: https://doi.org/10.1046/j.1365-2923.2002.01129.x
- **URL**: https://doi.org/10.1046/j.1365-2923.2002.01129.x

**ç·åˆã‚¹ã‚³ã‚¢**: 15.0

---


## ğŸ·ï¸ ã‚¿ã‚°

#è«–æ–‡æ¤œç´¢ #å­¦è¡“ç ”ç©¶ #general #é«˜è¢«å¼•ç”¨è«–æ–‡ #æœ€æ–°ç ”ç©¶

## ğŸ’¡ æ´»ç”¨æ–¹æ³•

ã“ã®æ¤œç´¢çµæœã¯ä»¥ä¸‹ã®ç”¨é€”ã§æ´»ç”¨ã§ãã¾ã™ï¼š

- **å–¶æ¥­ã‚¹ã‚­ãƒ«å‘ä¸Š**: ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ãƒ™ãƒ¼ã‚¹ã®å–¶æ¥­æ‰‹æ³•ã®å­¦ç¿’
- **ãƒãƒã‚¸ãƒ¡ãƒ³ãƒˆæ”¹å–„**: å­¦è¡“çš„æ ¹æ‹ ã«åŸºã¥ãçµ„ç¹”é‹å–¶
- **ç ”ä¿®è³‡æ–™ä½œæˆ**: è«–æ–‡ã®å¼•ç”¨ã«ã‚ˆã‚‹èª¬å¾—åŠ›ã®ã‚ã‚‹è³‡æ–™ä½œæˆ
- **æ›´ãªã‚‹ç ”ç©¶**: å¼•ç”¨æ–‡çŒ®ã‹ã‚‰ã®é–¢é€£ç ”ç©¶ã®ç™ºè¦‹

## ğŸ”— é–¢é€£ãƒªãƒ³ã‚¯

- [[è«–æ–‡æ¤œç´¢ã‚·ã‚¹ãƒ†ãƒ ä½¿ç”¨æ–¹æ³•]]
- [[å–¶æ¥­å¿ƒç†å­¦ç ”ç©¶ãƒãƒ¼ãƒˆ]]
- [[ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ãƒ™ãƒ¼ã‚¹å–¶æ¥­æˆ¦ç•¥]]

---

*ğŸ“š ã“ã®æ¤œç´¢çµæœã¯è«–æ–‡æ¤œç´¢ã‚·ã‚¹ãƒ†ãƒ ã«ã‚ˆã‚Šè‡ªå‹•ç”Ÿæˆã•ã‚Œã¾ã—ãŸ*
*ğŸ”„ æœ€æ–°ã®ç ”ç©¶ã«ã¤ã„ã¦ã¯å®šæœŸçš„ãªå†æ¤œç´¢ã‚’ãŠå‹§ã‚ã—ã¾ã™*
